EXPLORING THE INTERPLAY BETWEEN CARDIOVASCULAR DISEASE AND HORMONAL CHANGES DURING MENOPAUSE, WITH A FOCUS ON PREVENTIVE STRATEGIES
Keywords:
MENOPAUSE, TRIGGERS, FASTER, CVD SECONDARY ENDPOINTS, BMI, SBP, HS-CRPAbstract
Menopause triggers the faster development of cardiovascular disease (CVD) through estrogen deficiency, but the most effective preventive measures are a controversial issue. The current trial compared lifestyle interventions to hormone replacement therapy (HRT) by considering them as a combination of both interventions.
This was a prospective, randomized controlled trial recruiting 140 women of intermediate CVD risk who were aged 45–60 years old and were based in Iraq. The participants were randomly divided into Group A (lifestyle alone: 150-300 min/week of moderate-vigorous physical activity and a DASH diet plan) and Group B (lifestyle and transdermal estradiol 0.05mg/day and oral progesterone 100mg/day)
Individual changes in biomarkers and clinical events were considered as secondary endpoints. A mixed-effects ANOVA (=0.05) was used as an intention-to-treat technique.
The baseline data was even (mean age 52 of 4 years; BMI 27.6 of 3.9 kg / m 2). Group B had better decreases in SBP (120.001 vs 126.0013.00mmHg; p.02), LDL (118.001 vs 130.0013.00mg/dl; p.01), hs-CRP (2.001.1 vs 2.701.3.00mmol/L; p.01), and IMT (0.71.0009 vs 0.75.00
Early HRT is a preventive intervention that enhances the reduced CVD risk in perimenopausal women using a structured lifestyle program and ought to be incorporated in prevention initiatives. To support these findings, multicenter validation studies should be done.
